UNSPSC 51313003: Azelastine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C22H24ClN3O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0L591QR10I, chemically known as 1(2h)-phthalazinone, 4-((4-chlorophenyl)methyl)-2-(hexahydro-1-methyl-1h-azepin-4-yl)-, monohydrochloride but more generally known as azelastine hydrochloride, which bears US NIH Compound Identifier 54360.

UNSPSC 51313003 Azelastine hydrochloride is a Commodity code that nominally designates a specific antihistamine pharmaceutical, but the recent state and local procurement activity tagged under this code does not align with that scope. Seminole County, Florida posted an IFB in mid-2026 for naloxone and drug deactivation systems — opioid-reversal medication and harm-reduction equipment — which falls outside the pharmaceutical antihistamine family that the code's name implies. The mismatch suggests either a cataloging error in the county's procurement system or a vendor-uploaded code that does not reflect the actual commodity being solicited. State and local governments use UNSPSC codes to standardize procurement taxonomy, but coding discipline varies across jurisdictions, and pharmaceutical codes in particular see frequent misclassification when vendors or procurement staff apply codes without validation against actual product specifications.

The single recent opportunity on record is Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023 — a date that appears to be a historical record or data-entry error given the post date. The solicitation calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The county requires electronic bid submission through its e-Procurement Portal, compliance with drug-free workplace and E-Verify requirements, workers' compensation and commercial general liability insurance, and a fixed-fee pricing model. The contract structure includes a two-year initial term with a one-year renewal option and a three-month probationary termination clause. Without additional recent opportunities under this code, geographic concentration or issuing-body patterns cannot be assessed. Firms evaluating this code should verify that actual product specifications in future RFQs or IFBs align with their pharmaceutical or medical-device portfolio before pursuing.